Future Projections in Thyroid Eye Disease

Giuseppe Barbesino, Mario Salvi, Suzanne K Freitag, Giuseppe Barbesino, Mario Salvi, Suzanne K Freitag

Abstract

Background and aims: This review aims to summarize current and emerging therapies for treatment of thyroid eye disease (TED), in the light of novel understanding of pathogenetic mechanisms, leading to new treatment options and clinical trials.

Methods: We reviewed and analyzed peer-reviewed literature reporting recent translational studies and clinical trials in the treatment of TED. Searches were made at www.pubmed.gov with keywords "thyroid eye disease," "Graves' ophthalmopathy," "thyroid orbitopathy," and "Graves' orbitopathy."

Results: Surgery is reserved for rehabilitation in chronic TED or for emergent compressive optic neuropathy. Oral and intravenous glucocorticoid therapy has been used for decades with variable efficacy in acute TED, but results may be temporary and side effects significant. Nonsteroidal oral immunosuppressive agents offer modest benefit in TED. Several immunomodulatory monoclonal antibodies, including rituximab and tocilizumab, have shown efficacy for inactivating TED. Recently, teprotumumab, an insulin-like growth factor 1 receptor (IGF-1R) inhibitor, has demonstrated significant improvement in proptosis, clinical activity score, diplopia, and quality of life in patients with active TED, with good tolerability. Newly proposed TED therapies, currently in preclinical and clinical trial phases, include thyroid-stimulating hormone (TSH) receptor inhibitory drugs, RVT-1401, local anti-vascular endothelial growth factor therapy, IGF-1R drugs delivered subcutaneously and orally, and desensitization to the TSH receptor with modified TSH receptor peptides.

Conclusion: New, albeit incomplete, understanding of the molecular mechanisms of TED has led to new promising therapies and offered improved outcomes in TED patients. Their full role and their relationship to classical immune suppression should be clarified over the next few years.

Keywords: Graves’ disease; TSH receptor; glucocorticoids; insulin-like growth factor 1 receptor; teprotumumab; thyroid autoimmunity; thyroid eye disease.

© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society.

References

    1. Feliciello A, Porcellini A, Ciullo I, Bonavolonta G, Avvedimento EV, Fenzi G. Expression of thyrotropin-receptor mRNA in healthy and Graves’ disease retro-orbital tissue. Lancet. 1993;342(8867):337-338.
    1. Bahn RS. Current insights into the pathogenesis of Graves’ ophthalmopathy. Horm Metab Res. 2015;47(10):773-778.
    1. Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol. 2003;170(12):6348-6354.
    1. Pritchard J, Tsui S, Horst N, Cruikshank WW, Smith TJ. Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves’ disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor. J Immunol. 2004;173(5):3564-3569.
    1. Smith TJ, Hoa N. Immunoglobulins from patients with Graves’ disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab. 2004;89(10):5076-5080.
    1. Tsui S, Naik V, Hoa N, et al. . Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J Immunol. 2008;181(6):4397-4405.
    1. Douglas RS, Kahaly GJ, Patel A, et al. . Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341-352.
    1. Smith TJ, Kahaly GJ, Ezra DG, et al. . Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748-1761.
    1. Diniz SB, Cohen LM, Roelofs KA, Rootman DB. Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population. Ophthalmic Plast Reconstr Surg. 2021;37(6):583-591.
    1. Douglas RS, Kahaly GJ, Ugradar S, et al. . Teprotumumab efficacy, safety and durability in longer duration thyroid eye disease and retreatment: optic-X study. Ophthalmology. 2022:129(4):438-449.
    1. Ugradar S, Kang J, Kossler AL, et al. . Teprotumumab for the treatment of chronic thyroid eye disease. Eye (Lond). Published online July 9, 2021. doi:10.1038/s41433-021-01593-z
    1. Bartalena L, Krassas GE, Wiersinga W, et al. ; European Group on Graves’ Orbitopathy. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97(12):4454-4463.
    1. Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab. 2005;90(9):5234-5240.
    1. Finn AP, Bleier B, Cestari DM, et al. . A retrospective review of orbital decompression for thyroid orbitopathy with endoscopic preservation of the inferomedial orbital bone strut. Ophthalmic Plast Reconstr Surg. 2017;33(5):334-339.
    1. Stahr K, Eckstein A, Buschmeier M, et al. . Risk factors for new onset diplopia after graduated orbital decompression. Ophthalmic Plast Reconstr Surg. 2021;37(6):564-570.
    1. Olivari N. Transpalpebral decompression of endocrine ophthalmopathy (Graves’ disease) by removal of intraorbital fat: experience with 147 operations over 5 years. Plast Reconstr Surg. 1991;87(4):627-641; discussion 642-643.
    1. Chin YH, Ng CH, Lee MH, et al. . Prevalence of thyroid eye disease in Graves’ disease: a meta-analysis and systematic review. Clin Endocrinol (Oxf). 2020;93(4):363-374.
    1. Rajabi MT, Jafari H, Mazloumi M, et al. . Lower lid retraction in thyroid orbitopathy: lamellar shortening or proptosis? Int Ophthalmol. 2014;34(4):801-804.
    1. Rootman DB, Golan S, Pavlovich P, Rootman J. Postoperative changes in strabismus, ductions, exophthalmometry, and eyelid retraction after orbital decompression for thyroid orbitopathy. Ophthalmic Plast Reconstr Surg. 2017;33(4):289-293.
    1. Choi SW, Lee JY, Lew H. Customized orbital decompression surgery combined with eyelid surgery or strabismus surgery in mild to moderate thyroid-associated ophthalmopathy. Korean J Ophthalmol. 2016;30(1):1-9.
    1. Bernardini FP, Skippen B, Zambelli A, Riesco B, Devoto MH. Simultaneous aesthetic eyelid surgery and orbital decompression for rehabilitation of thyroid eye disease: the one-stage approach. Aesthet Surg J. 2018;38(10):1052-1061.
    1. Quaranta-Leoni FM, Di Marino M, Leonardi A, Verrilli S, Romeo R. Single-stage orbital decompression, strabismus and eyelid surgery in moderate to severe thyroid associated orbitopathy. Orbit. 2022;41(2):184-192.
    1. Chandler GN, Hartfall SJ. Cortisone and ACTH in exophthalmic ophthalmoplegia. Lancet. 1952;1(6713):847-851.
    1. Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21(2):168-199.
    1. Nagayama Y, Izumi M, Kiriyama T, et al. . Treatment of Graves’ ophthalmopathy with high-dose intravenous methylprednisolone pulse therapy. Acta Endocrinol (Copenh). 1987;116(4):513-518.
    1. Dandona P, Havard CW, Mier A. Methylprednisolone and Graves’ ophthalmopathy. BMJ. 1989;298(6676):830-830.
    1. Kendall-Taylor P, Crombie AL, Stephenson AM, Hardwick M, Hall K. Intravenous methylprednisolone in the treatment of Graves’ ophthalmopathy. BMJ. 1988;297(6663):1574-1578.
    1. Zang S, Ponto KA, Pitz S, Kahaly GJ. Dose of intravenous steroids and therapy outcome in Graves’ orbitopathy. J Endocrinol Invest. 2011;34(11):876-880.
    1. Aktaran S, Akarsu E, Erbagci I, Araz M, Okumus S, Kartal M. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves’ ophthalmopathy. Int J Clin Pract. 2007;61(1):45-51.
    1. Marcocci C, Bartalena L, Tanda ML, et al. . Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves’ ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab. 2001;86(8):3562-3567.
    1. Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I, Leibovici L. Treatment modalities for Graves’ ophthalmopathy: systematic review and metaanalysis. J Clin Endocrinol Metab. 2009;94(8):2708-2716.
    1. Marino M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marocci C. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves’ ophthalmopathy. Thyroid. 2004;14(5):403-406.
    1. Broen JCA, van Laar JM. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. Nat Rev Rheumatol. 2020;16(3):167-178.
    1. Ye X, Bo X, Hu X, et al. . Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves’ orbitopathy. Clin Endocrinol (Oxf). 2017;86(2):247-255.
    1. Kahaly GJ, Riedl M, Konig J, et al. ; European Group on Graves’ Orbitopathy (EUGOGO). Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018;6(4):287-298.
    1. Bartalena L, Kahaly GJ, Baldeschi L, et al. . The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185(4):G43-G67.
    1. Kahaly G, Schrezenmeir J, Krause U, et al. . Ciclosporin and prednisone v. prednisone in treatment of Graves’ ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest. 1986;16(5):415-422.
    1. Prummel MF, Mourits MP, Berghout A, et al. . Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N Engl J Med. 1989;321(20):1353-1359.
    1. Rajendram R, Taylor PN, Wilson VJ, et al. . Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6(4):299-309.
    1. Nilsson A, Tsoumani K, Planck T. Statins decrease the risk of orbitopathy in newly diagnosed patients with graves disease. J Clin Endocrinol Metab. 2021;106(5):1325-1332.
    1. Lanzolla G, Sabini E, Leo M, et al. . Statins for Graves’ orbitopathy (STAGO): a Phase 2, open-label, adaptive, single centre, randomised clinical trial. Lancet Diabetes Endocrinol. 2021;9(11):733-742.
    1. Heisel CJ, Riddering AL, Andrews CA, Kahana A. Serum vitamin D deficiency is an independent risk factor for thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2020;36(1):17-20.
    1. Ferrari SM, Fallahi P, Elia G, et al. . Novel therapies for thyroid autoimmune diseases: an update. Best Pract Res Clin Endocrinol Metab. 2020;34(1):101366.
    1. Fallahi P, Ferrari SM, Elia G, et al. . Cytokines as targets of novel therapies for Graves’ ophthalmopathy. Front Endocrinol (Lausanne). 2021;12:654473.
    1. Salvi M, Vannucchi G, Curro N, et al. . Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action. Arch Ophthalmol. 2012;130(1):122-124.
    1. Salvi M, Vannucchi G, Beck-Peccoz P. Potential utility of rituximab for Graves’ orbitopathy. J Clin Endocrinol Metab. 2013;98(11):4291-4299.
    1. Silkiss RZ, Reier A, Coleman M, Lauer SA. Rituximab for thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2010;26(5): 310-314.
    1. Stan MN, Garrity JA, Carranza Leon BG, et al. . Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab. 2015;100(2):432-441.
    1. Salvi M, Vannucchi G, Curro N, et al. . Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100(2):422-431.
    1. Stan MN, Salvi M. Management of endocrine disease: rituximab therapy for Graves’ orbitopathy—lessons from randomized control trials. Eur J Endocrinol. 2017;176(2):R101-R109.
    1. Chen J, Chen G, Sun H. Intravenous rituximab therapy for active Graves’ ophthalmopathy: a meta-analysis. Hormones (Athens). 2021;20(2):279-286.
    1. Vannucchi G, Campi I, Covelli D, et al. . Efficacy profile and safety of very low-dose rituximab in patients with Graves’ orbitopathy. Thyroid. 2021;31(5):821-828.
    1. Deltour JB, d’Assigny Flamen M, Ladsous M, et al. . Efficacy of rituximab in patients with Graves’ orbitopathy: a retrospective multicenter nationwide study. Graefes Arch Clin Exp Ophthalmol. 2020;258(9):2013-2021.
    1. Smolen JS, Aletaha D, Barton A, et al. . Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.
    1. Salvi M, Girasole G, Pedrazzoni M, et al. . Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves’ disease. J Clin Endocrinol Metab. 1996;81(8):2976-2979.
    1. Slowik M, Urbaniak-Kujda D, Bohdanowicz-Pawlak A, et al. . CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves’ orbitopathy and correlate with disease activity. Endocr Res. 2012;37(2):89-95.
    1. Perez-Moreiras JV, Alvarez-Lopez A, Gomez EC. Treatment of active corticosteroid-resistant Graves’ orbitopathy. Ophthalmic Plast Reconstr Surg. 2014;30(2):162-167.
    1. Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. ; Tocilizumab in Graves Orbitopathy Study Group. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical Trial. Am J Ophthalmol. 2018;195:181-190.
    1. Favero V, Curro N, Campi I, et al. . Efficacy of the anti-BAFF monoclonal antibody belimumab vs methylprednisolone in active moderate-severe graves’ orbitopathy: preliminary analysis of a randomized controlled trial. Endocrine Abstracts. 2021;73:YI2. doi:10.1530/endoabs.73.YI2
    1. Kurzrock R, Patnaik A, Aisner J, et al. . A Phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res. 2010;16(8):2458-2465.
    1. Kahaly GJ, Douglas RS, Holt RJ, Sile S, Smith TJ. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. 2021;9(6):360-372.
    1. Diniz SB, Cohen LM, Roelofs KA, Rootman DB. Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population. Ophthalmic Plast Reconstr Surg. 2021;37(6):583-591.
    1. Ozzello DJ, Dallalzadeh LO, Liu CY. Teprotumumab for chronic thyroid eye disease. Orbit. Published online July 1, 2021. doi:10.1080/01676830.2021.1933081
    1. Gao L, Nakagawa T. Insulin-like growth factor 1: role in the auditory system and therapeutic potential in otology. Curr Opin Otolaryngol Head Neck Surg. 2020;28(5):286-290.
    1. Belinsky I, Creighton FX Jr, Mahoney N, et al. . Teprotumumab and hearing loss: case series and proposal for audiologic monitoring. Ophthalmic Plast Reconstr Surg. 2022;38(1):73-78.
    1. Jain AP, Gellada N, Ugradar S, Kumar A, Kahaly G, Douglas R. Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease. Br J Ophthalmol. 2022;106(2):165-171.
    1. Prabhu RS, Liebman L, Wojno T, Hayek B, Hall WA, Crocker I. Clinical outcomes of radiotherapy as initial local therapy for Graves’ ophthalmopathy and predictors of the need for post-radiotherapy decompressive surgery. Radiat Oncol. 2012;7:95.
    1. Grassi P, Strianese D, Piscopo R, Pacelli R, Bonavolonta G. Radiotherapy for the treatment of thyroid eye disease-a prospective comparison: is orbital radiotherapy a suitable alternative to steroids? Ir J Med Sci. 2017;186(3):647-652.
    1. Oeverhaus M, Witteler T, Lax H, Esser J, Fuhrer D, Eckstein A. Combination therapy of intravenous steroids and orbital irradiation is more effective than intravenous steroids alone in patients with Graves’ orbitopathy. Horm Metab Res. 2017;49(10):739-747.
    1. Sterker I, Tegetmeyer H, Papsdorf K, Fuhrer-Sakel D. Effect of combined intravenous glucocorticoids and orbital radiotherapy in restoring driving competency in patients with Graves’ orbitopathy. Horm Metab Res. 2009;41(5):391-396.
    1. Shams PN, Ma R, Pickles T, Rootman J, Dolman PJ. Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease. Am J Ophthalmol. 2014;157(6):1299-1305.
    1. Bagheri A, Abbaszadeh M, Yazdani S. Intraorbital steroid injection for active thyroid ophthalmopathy. J Ophthalmic Vis Res. 2020;15(1):69-77.
    1. Alkawas AA, Hussein AM, Shahien EA. Orbital steroid injection versus oral steroid therapy in management of thyroid-related ophthalmopathy. Clin Exp Ophthalmol. 2010;38(7):692-697.
    1. Wong LL, Lee NG, Amarnani D, et al. . Orbital angiogenesis and lymphangiogenesis in thyroid eye disease: an analysis of vascular growth factors with clinical correlation. Ophthalmology. 2016;123(9):2028-2036.
    1. Geoerger B, Brasme JF, Daudigeos-Dubus E, et al. . Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma. Eur J Cancer. 2010;46(18):3251-3262.
    1. Dickinson B, Pestano L, Bedian V, Clausen C. VRDN-002, a second generation insulin like growth factor-1 receptor (IGF-1R) antagonist antibody for thyroid eye disease: preclinical pharmacokinetic profile and clinical promise. Thyroid. 2021;31:A-16.
    1. Furmaniak J, Sanders J, Young S, et al. . In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70). Auto Immun Highlights. 2012;3(1):19-25.
    1. Furmaniak J, Sanders J, Clark J, et al. . Preclinical studies on the toxicology, pharmacokinetics and safety of K1-70(TM) a human monoclonal autoantibody to the TSH receptor with TSH antagonist activity. Auto Immun Highlights. 2019;10(1):11.
    1. Ryder M, Wentworth M, Algeciras-Schimnich A, et al. . Blocking the thyrotropin receptor with K1-70 in a patient with follicular thyroid cancer, Graves’ disease, and Graves’ ophthalmopathy. Thyroid. 2021;31(10):1597-1602.
    1. Neumann S, Krieger CC, Gershengorn MC. Targeting TSH and IGF-1 receptors to treat thyroid eye disease. Eur Thyroid J. 2020;9(suppl 1):59-65.
    1. Krause G, Marcinkowski P. Intervention strategies into glycoprotein hormone receptors for modulating (Mal-)function, with special emphasis on the TSH receptor. Horm Metab Res. 2018;50(12):894-907.
    1. Marcinkowski P, Hoyer I, Specker E, et al. . A new highly thyrotropin receptor-selective small-molecule antagonist with potential for the treatment of Graves’ orbitopathy. Thyroid. 2019;29(1):111-123.
    1. Eckstein AK, Plicht M, Lax H, et al. . Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006;91(9):3464-3470.
    1. Nicoli F, Lanzolla G, Mantuano M, et al. . Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves’ orbitopathy. J Endocrinol Invest. 2021;44(3): 581-585.
    1. Minich WB, Dehina N, Welsink T, et al. . Autoantibodies to the IGF1 receptor in Graves’ orbitopathy. J Clin Endocrinol Metab. 2013;98(2):752-760.
    1. Marino M, Rotondo Dottore G, Ionni I, et al. . Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy. J Endocrinol Invest. 2019;42(4):471-480.
    1. Kahaly G, Schuler M, Sewell AC, Bernhard G, Beyer J, Krause U. Urinary glycosaminoglycans in Graves’ ophthalmopathy. Clin Endocrinol (Oxf). 1990;33(1):35-44.
    1. Perros P, Weightman DR, Crombie AL, Kendall-Taylor P. Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol (Copenh). 1990;122(1):8-12.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅